Neurocrine Biosciences' Soleno Therapeutics Announces Late-Breaking Data At ENDO 2026 Showing Two Years Of VYKAT XR After 16‑Week Withdrawal Sustained Improvements In Hyperphagia And Behavioral Symptoms In PWS

뉴스 본문을 불러오고 있어요.

Neurocrine Biosciences' Soleno Therapeutics Announces Late-Breaking Data At ENDO 2026 Showing Two Years Of VYKAT XR After 16‑Week Withdrawal Sustained Improvements In Hyperphagia And Behavioral Symptoms In PWS | 웨이프 WAPE

Neurocrine Biosciences' Soleno Therapeutics Announces Late-Breaking Data At ENDO 2026 Showing Two Years Of VYKAT XR After 16‑Week Withdrawal Sustained Improvements In Hyperphagia And Behavioral Symptoms In PWS

기사 요약

관련 종목

댓글 —